Plasma Selenium, Manganese Superoxide Dismutase, and Intermediate- or High-Risk Prostate Cancer Although all authors completed the disclosure declaration, the following author(s) indicated a financial ...
AB Science SA (Euronext – FR0010557264 – AB) will host a live webcast on May 25, 2021 with key opinion leaders to discuss recently reported results from the Phase 2B/3 masitinib trial in prostate ...
CHICAGO–The addition of docetaxel to hormonal therapy at an early stage in nonmetastatic high-risk prostate cancer patients reduces risk of prostate-specific antigen (PSA) relapse by 9–26%, reported ...
Inhibiting a protein involved in bone metabolism can delay the onset of bone metastases common in men with prostate cancer resistant to hormone treatment. The research on the effects of the monoclonal ...
Stockholm, Sweden: Inhibiting a protein involved in bone metabolism can delay the onset of the bone metastases which are common in men with a particular form of prostate cancer, a researcher will tell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results